Cullinan Oncology, Inc.

NASDAQ:CGEM

11.6 (USD) • At close December 20, 2024
Bedrijfsnaam Cullinan Oncology, Inc.
Symbool CGEM
Munteenheid USD
Prijs 11.6
Beurswaarde 675,440,160
Dividendpercentage 0%
52-weken bereik 9.24 - 30.189
Industrie Biotechnology
Sector Healthcare
CEO Mr. Nadim Ahmed
Website https://www.cullinanoncology.com

An error occurred while fetching data.

Over Cullinan Oncology, Inc.

Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients

Vergelijkbare Aandelen

Inhibrx, Inc. logo

Inhibrx, Inc.

INBX

14.6 USD

Intercept Pharmaceuticals, Inc. logo

Intercept Pharmaceuticals, Inc.

ICPT

19 USD

Nano-X Imaging Ltd. logo

Nano-X Imaging Ltd.

NNOX

6.76 USD

ANI Pharmaceuticals, Inc. logo

ANI Pharmaceuticals, Inc.

ANIP

53.35 USD

Caribou Biosciences, Inc. logo

Caribou Biosciences, Inc.

CRBU

1.8 USD

Century Therapeutics, Inc. logo

Century Therapeutics, Inc.

IPSC

1.1 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)